Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies

In Partnership With:

Partner | Cancer Centers | <b>John Theurer Cancer Center, Hackensack University Medical Center</b>

Andre H. Goy, MD, discusses updates in precision medicine.

Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Service, chairman & chief physician officer, John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology, Hackensack Meridian School of Medicine at Seton Hall University, professor of medicine, Georgetown University, discusses updates in precision medicine.

The use of CAR T-cell therapy, such as axicabtagene ciloleucel (axi-cel; Yescarta) has been shown to be beneficial in hematologic malignancies, and it is important to understand that this has the potential to be a curative therapy, Goy says. Oncologists must ensure that patients are referred early in order toderive the most benefit from this treatment, Goy explains.

Moreover, when looking at patients in the space, it must be understood that oncologists continue to investigate beyond a single type of cell in order to reset the immune system in in a suppressive environment induced by the cancer cells, Goy concludes.